[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].

Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie.

High-Throughput Nucleotide Sequencing Humans Mutation Pathology, Molecular Precision Medicine Surveys and Questionnaires Urinary Bladder Neoplasms / genetics

Bladder cancer Molecular pathology Next generation sequencing Precision oncology Targeted treatment

Journal

Der Urologe. Ausg. A

ISSN: 1433-0563

Titre abrégé: Urologe A

Pays: Germany

ID NLM: 1304110

Informations de publication

Date de publication:
Mar 2020

Historique:

pubmed: 22 9 2019

medline: 14 3 2020

entrez: 22 9 2019

Statut: ppublish

Résumé

Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged. Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology. We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions. A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available. So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.

Sections du résumé

BACKGROUND BACKGROUND

Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged.

AIM OBJECTIVE

Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology.

METHODS METHODS

We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions.

RESULTS RESULTS

A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available.

DISCUSSION CONCLUSIONS

So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.

Identifiants

DOI: 10.1007/s00120-019-01046-2 PMID: 31541269

pubmed: 31541269

doi: 10.1007/s00120-019-01046-2

pii: 10.1007/s00120-019-01046-2

doi:

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

Pagination

318-325

Références

Bladder Cancer. 2016 Jan 7;2(1):37-47

pubmed: 27376123

J Clin Oncol. 2017 Jan 10;35(2):157-165

pubmed: 27870574

Eur Urol. 2008 Oct;54(4):835-43

pubmed: 18166262

Hum Mutat. 2008 Nov;29(11):1282-91

pubmed: 18951446

Clin Cancer Res. 2012 Jun 15;18(12):3377-86

pubmed: 22553347

Cancer Cell. 2014 Feb 10;25(2):152-65

pubmed: 24525232

Genet Med. 2015 May;17(5):405-24

pubmed: 25741868

Nature. 2014 Mar 20;507(7492):315-22

pubmed: 24476821

Eur Urol. 2014 Feb;65(2):360-6

pubmed: 24018021

Cell. 2017 Oct 19;171(3):540-556.e25

pubmed: 28988769

J Hematol Oncol. 2014 Jul 20;7:47

pubmed: 25042800

Cell. 2017 Feb 9;168(4):584-599

pubmed: 28187282

Am J Surg Pathol. 2015 Jan;39(1):127-31

pubmed: 25118812

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5

pubmed: 24520177

Cancer Discov. 2018 Aug;8(8):OF6

pubmed: 29950346